Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -64.44% is 164% below its 5-year average of -24.38%, around the middle of its 5-year range (-122.35%–19.27%).
18.28% above its 12-month average of -78.85%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -122.35%.
EBITDA MARGIN
-64.44%
EBITDA MARGIN AVG TTM
-78.85%
EBITDA MARGIN AVG 3Y
-44.53%
EBITDA MARGIN AVG 5Y
-24.38%
EBITDA MARGIN AVG 10Y
1.17%
EBITDA MARGIN AVG 15Y
-20.26%
EBITDA MARGIN AVG 20Y
-16.88%
CURRENT VS TTM AVG
+18.28%
CURRENT VS 3Y AVG
-44.72%
CURRENT VS 5Y AVG
-164.34%
CURRENT VS 10Y AVG
-5613.11%
CURRENT VS 15Y AVG
-218.13%
CURRENT VS 20Y AVG
-281.74%
Vanda Pharmaceuticals Inc.
Market Cap
$271.81M
EBITDA Margin
-64.44%
TTM Avg
-78.85%
3Y Avg
-44.53%
5Y Avg
-24.38%
Market Cap
$270.80M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.92M
EBITDA Margin
-2082.59%
TTM Avg
-1743.06%
3Y Avg
-1015.79%
5Y Avg
-806.48%
Market Cap
$266.59M
EBITDA Margin
-2882.46%
TTM Avg
-2207.86%
3Y Avg
-1135.55%
5Y Avg
-791.10%
Market Cap
$265.78M
EBITDA Margin
-768.62%
TTM Avg
-551.06%
3Y Avg
-374.75%
5Y Avg
-290.29%
Market Cap
$280.37M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
EBITDA Margin
-58.29%
TTM Avg
-89.32%
3Y Avg
-189.95%
5Y Avg
-208.07%
Market Cap
$281.54M
EBITDA Margin
-25.38%
TTM Avg
-1946.60%
3Y Avg
-1509.96%
5Y Avg
-1364.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | $271.81M | -64.44% | -78.85% | -44.53% | -24.38% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.80M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -2082.59% | -1743.06% | -1015.79% | -806.48% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | -2882.46% | -2207.86% | -1135.55% | -791.10% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | -768.62% | -551.06% | -374.75% | -290.29% |
| Scribe Therapeutics Inc. (SCTX)vs › | $264.25M | N/A | N/A | N/A | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $280.37M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | -58.29% | -89.32% | -189.95% | -208.07% |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.54M | -25.38% | -1946.60% | -1509.96% | -1364.90% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | -7643.91% | -11162.31% | -5581.16% | -3720.77% |
Gross Margin
92.8%
EBITDA Margin
-64.4%
Operating Margin
-70.0%
Net Margin
-127.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -122.35% |
| 2026-03-31 | -90.29% |
| 2025-12-31 | -60.28% |
| 2025-09-30 | -51.96% |
| 2025-06-30 | -69.38% |
| 2025-03-31 | -87.07% |
| 2024-12-31 | -15.62% |
| 2024-09-30 | -18.96% |
| 2024-06-30 | -16.20% |
| 2024-03-31 | -14.77% |
| 2023-12-31 | -13.11% |
| 2023-09-30 | -13.95% |
| 2023-06-30 | -4.92% |
| 2023-03-31 | 4.28% |
| 2022-12-31 | 11.31% |
| 2022-09-30 | 7.02% |
| 2022-06-30 | 6.45% |
| 2022-03-31 | -11.57% |
| 2021-12-31 | 13.73% |
| 2021-09-30 | 16.44% |
| 2021-06-30 | 19.27% |
| 2021-03-31 | 17.64% |
| 2020-12-31 | 16.50% |
| 2020-09-30 | 14.03% |
| 2020-06-30 | 15.89% |
| 2020-03-31 | 1.03% |
| 2019-12-31 | 8.17% |
| 2019-09-30 | 19.31% |
| 2019-06-30 | 17.97% |
| 2019-03-31 | -3.58% |
| 2018-12-31 | 17.97% |
| 2018-09-30 | 14.21% |
| 2018-06-30 | 9.10% |
| 2018-03-31 | 7.21% |
| 2017-12-31 | -3.88% |
| 2017-09-30 | -10.04% |
| 2017-06-30 | -2.83% |
| 2017-03-31 | -19.25% |
| 2016-12-31 | 3.79% |
| 2016-09-30 | 6.52% |
| 2016-06-30 | -5.13% |
| 2016-03-31 | -28.66% |
| 2015-12-31 | -37.52% |
| 2015-09-30 | -23.28% |
| 2015-06-30 | -9.12% |
| 2015-03-31 | -27.13% |
| 2014-12-31 | 456.92% |
| 2014-09-30 | -5.28% |
| 2014-06-30 | -193.23% |
| 2014-03-31 | -283.15% |
| 2013-12-31 | -83.00% |
| 2013-09-30 | -57.73% |
| 2013-06-30 | -31.64% |
| 2013-03-31 | -47.72% |
| 2012-12-31 | -76.40% |
| 2012-09-30 | -60.55% |
| 2012-06-30 | -90.95% |
| 2012-03-31 | -93.56% |
| 2011-12-31 | -63.87% |
| 2011-09-30 | -36.59% |
| 2011-06-30 | -14.54% |
| 2011-03-31 | 6.04% |
| 2010-12-31 | 16.07% |
| 2010-09-30 | 16.56% |
| 2010-06-30 | 19.46% |
| 2010-03-31 | 53.22% |
| 2009-12-31 | -192.85% |
| 2008-03-31 | -575.48% |
